{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T02:36:34Z","timestamp":1785551794849,"version":"3.56.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.bbmt.2018.12.064","type":"journal-article","created":{"date-parts":[[2018,12,20]],"date-time":"2018-12-20T03:45:34Z","timestamp":1545277534000},"page":"932-940","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Busulfan- or Thiotepa-Based Conditioning in Myelofibrosis: A Phase II Multicenter Randomized Study from the GITMO Group"],"prefix":"10.1016","volume":"25","author":[{"given":"Francesca","family":"Patriarca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Masciulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Bacigalupo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Bregante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Pavoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Chiara","family":"Finazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Bosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Narni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Messina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio Paolo","family":"Alessandrino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo Michele","family":"Carella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Milone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetto","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Mammoliti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Fanin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1544-9911","authenticated-orcid":false,"given":"Francesca","family":"Bonifazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Rambaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2018.12.064_bib0001","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.12.064_bib0002","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","volume":"29","author":"Gangat","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2018.12.064_bib0003","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.12.064_bib0004","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/leu.2015.233","article-title":"Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT\/ELN International Working Group","volume":"29","author":"Kr\u00f6ger","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2018.12.064_bib0005","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/leu.2016.148","article-title":"Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis","volume":"30","author":"Harrison","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2018.12.064_bib0006","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2018.12.064_bib0007","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3324\/haematol.2014.115840","article-title":"Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I","volume":"100","author":"Verstovsek","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2018.12.064_bib0008","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1182\/blood-2003-06-1856","article-title":"Allogeneic hematopoietic stem cell transplantation for myelofibrosis","volume":"102","author":"Deeg","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.12.064_bib0009","first-page":"2831","volume":"93","author":"Guardiola","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.12.064_bib0010","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1056\/NEJM200008313430913","article-title":"Myelofibrosis with myeloid metaplasia","volume":"343","author":"Guardiola","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2018.12.064_bib0011","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.bbmt.2006.11.004","article-title":"Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia","volume":"13","author":"Kerbauy","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.12.064_bib0012","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.bbmt.2009.10.025","article-title":"Outcome of transplantation for myelofibrosis","volume":"16","author":"Ballen","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.12.064_bib0013","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1038\/bmt.2010.14","article-title":"The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplantation study","volume":"45","author":"Stewart","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.12.064_bib0014","doi-asserted-by":"crossref","first-page":"5264","DOI":"10.1182\/blood-2009-07-234880","article-title":"Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation","volume":"114","author":"Kr\u00f6ger","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.12.064_bib0015","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1182\/blood.V84.11.3948.bloodjournal84113948","article-title":"Successful engraftment of T-cell-depleted haploidentical \u201cthree-loci\u201d incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum","volume":"84","author":"Aversa","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.12.064_bib0016","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.3324\/haematol.12828","article-title":"Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)","volume":"93","author":"Patriarca","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2018.12.064_bib0017","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1046\/j.1365-2141.2000.02123.x","article-title":"Reduced-intensity thiotepa-cyclophosphamide conditioning for allogeneic haemopoietic stem cell transplants (HSCT) in patients up to 60 years of age","volume":"109","author":"Raiola","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2018.12.064_bib0018","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1038\/leu.2012.55","article-title":"Outcome of patients activating an unrelated donor search: the impact of transplant with reduced intensity conditioning in a large cohort of consecutive high-risk patients","volume":"26","author":"Rambaldi","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2018.12.064_bib0019","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/bmt.2009.188","article-title":"Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type","volume":"45","author":"Bacigalupo","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.12.064_bib0020","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.12.064_bib0021","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and Staging Working Group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.12.064_bib0022","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1182\/blood-2006-03-009746","article-title":"International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT)","volume":"108","author":"Tefferi","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.12.064_bib0023","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2014-04-572545","article-title":"MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis","volume":"124","author":"Rondelli","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.12.064_bib0024","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.bbmt.2013.10.018","article-title":"Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the Center for International Blood and Marrow Transplant Research","volume":"20","author":"Gupta","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.12.064_bib0025","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/j.bbmt.2016.02.019","article-title":"Outcome after transplantation according to reduced-intensity conditioning regimen in patients undergoing transplantation for myelofibrosis","volume":"22","author":"Robin","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.12.064_bib0026","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1365-2141.2011.08582.x","article-title":"Allogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60-78 years of age","volume":"153","author":"Samuelson","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2018.12.064_bib0027","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/bmt.2009.10","article-title":"A retrospective comparison of conventional intensity conditioning and reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in myelofibrosis","volume":"44","author":"Gupta","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.12.064_bib0028","doi-asserted-by":"crossref","unstructured":"Jain T, Kunze KL, Temkit M, et al. Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis. Bone Marrow Transplant. 2018 https:\/\/doi.org\/10.1038\/s41409-018-0226-1. [Epub ahead of print]","DOI":"10.1038\/s41409-018-0226-1"},{"key":"10.1016\/j.bbmt.2018.12.064_bib0029","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1182\/blood-2011-02-337261","article-title":"Applicability of a \u201cPick a Winner\u201d trial design to acute myeloid leukemia","volume":"118","author":"Hills","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.12.064_bib0030","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.bbmt.2017.09.016","article-title":"Hematopoietic cell transplantation for myelofibrosis: the Dynamic International Prognostic Scoring System plus risk predicts post-transplant outcomes","volume":"24","author":"Samuelson Bannow","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.12.064_bib0031","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1182\/blood-2009-12-260588","article-title":"Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis","volume":"116","author":"Alchalby","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.12.064_bib0032","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1038\/bmt.2009.367","article-title":"Screening and monitoring of MPL W515L mutation with real-time PCR in patients with myelofibrosis undergoing allogeneic-SCT","volume":"45","author":"Alchalby","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.12.064_bib0033","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/bmt.2016.128","article-title":"Similar outcome of calreticulin type I and calreticulin type II mutations following RIC allogeneic haematopoietic stem cell transplantation for myelofibrosis","volume":"51","author":"Christopeit","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.12.064_bib0034","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.bbmt.2017.03.034","article-title":"Impact of molecular genetics on outcome in myelofibrosis patients after allogeneic stem cell transplantation","volume":"23","author":"Kr\u00f6ger","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.12.064_bib0035","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1016\/j.bbmt.2016.08.029","article-title":"Outcome of allogeneic hematopoietic stem cell transplantation for patients with chronic and advanced phase myelofibrosis","volume":"22","author":"Keyzner","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.12.064_bib0036","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1038\/bmt.2015.172","article-title":"Effect of conditioning regimens on graft failure in myelofibrosis: a retrospective analysis","volume":"50","author":"Slot","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.12.064_bib0037","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.bbmt.2015.09.028","article-title":"Improved outcome of alternative donor transplantations in patients with myelofibrosis: from unrelated to haploidentical family donors","volume":"22","author":"Bregante","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.12.064_bib0038","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/j.1365-2141.2005.05373.x","article-title":"Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis","volume":"128","author":"Kr\u00f6ger","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2018.12.064_bib0039","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1182\/blood-2004-11-4299","article-title":"Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia","volume":"105","author":"Rondelli","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.12.064_bib0040","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1038\/bmt.2014.131","article-title":"Allogeneic hematopoietic cell transplantation for myelofibrosis using fludarabine-, intravenous busulfan- and low-dose TBI-based conditioning","volume":"49","author":"Shanavas","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.12.064_bib0041","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.6004\/jnccn.2017.0157","article-title":"NCCN guidelines insights: myeloproliferative neoplasms, version 2.2018","volume":"15","author":"Mesa","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.bbmt.2018.12.064_bib0042","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.bbmt.2017.04.025","article-title":"Transplantation in myelofibrosis reaches the molecular age","volume":"23","author":"Palmer","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.12.064_bib0043","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1182\/blood-2014-10-608315","article-title":"Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis","volume":"125","author":"Kr\u00f6ger","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.12.064_bib0044","first-page":"3301","article-title":"Which patients with myelofibrosis should receive allogeneic stem cell transplantation? a decision analysis based on the systematic review of 4,341 patients","volume":"130","author":"Marchetti","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.12.064_bib0045","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1200\/JCO.2017.76.4886","article-title":"MIPSS70: Mutation-Enhanced International Prognostic Score System for transplantation-age patients with primary myelofibrosis","volume":"36","author":"Guglielmelli","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2018.12.064_bib0046","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1038\/leu.2017.169","article-title":"A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis","volume":"31","author":"Passamonti","year":"2017","journal-title":"Leukemia"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879118308863?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879118308863?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:07:19Z","timestamp":1761059239000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879118308863"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S1083879118308863"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.064","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Busulfan- or Thiotepa-Based Conditioning in Myelofibrosis: A Phase II Multicenter Randomized Study from the GITMO Group","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.064","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Inc. on behalf of American Society for Blood and Marrow Transplantation.","name":"copyright","label":"Copyright"}]}}